{
 "disease": "pancreatic-cancer",
 "label": "Pancreatic cancer",
 "url": "https://usebiotransfer.org/disease/pancreatic-cancer/",
 "built": "2026-09-11",
 "facts_hash": {
  "answers": "012ca9208644",
  "targets": "1b3147b378d7"
 },
 "sources": {
  "targets": "Open Targets Platform GraphQL API v4",
  "trials": "ClinicalTrials.gov API v2"
 },
 "retrieved": {
  "targets": "2026-09-11",
  "trials": "2026-09-11"
 },
 "query": {
  "endpoint": "https://clinicaltrials.gov/api/v2/studies",
  "shape": "query.cond=<disease>&query.intr=<term>&pageSize=200",
  "active_statuses": [
   "ACTIVE_NOT_RECRUITING",
   "ENROLLING_BY_INVITATION",
   "NOT_YET_RECRUITING",
   "RECRUITING"
  ],
  "dedup": "by NCT id across synonyms",
  "study_types": "interventional counted in headline; observational reported separately",
  "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search"
 },
 "targets": [
  {
   "symbol": "KRAS",
   "ensembl": "ENSG00000133703",
   "n_drug_entries": 3,
   "n_distinct_drugs": 3,
   "drugs": {
    "ADAGRASIB": "APPROVAL",
    "SALIRASIB": "PHASE_2",
    "SOTORASIB": "APPROVAL"
   },
   "approved": [
    "ADAGRASIB",
    "SOTORASIB"
   ],
   "n_approved": 2,
   "approved_for": {
    "ADAGRASIB": [
     "non-small cell lung carcinoma"
    ],
    "SOTORASIB": [
     "non-small cell lung carcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "TP53",
   "ensembl": "ENSG00000141510",
   "n_drug_entries": 9,
   "n_distinct_drugs": 8,
   "drugs": {
    "ALRIZOMADLIN": "PHASE_2",
    "CENERSEN": "PHASE_2",
    "CONTUSUGENE LADENOVEC": "PHASE_3",
    "EPRENETAPOPT": "PHASE_3",
    "IDASANUTLIN": "PHASE_3",
    "NAVTEMADLIN": "PHASE_3",
    "SIREMADLIN": "PHASE_2",
    "TEPRASIRAN": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CDKN2A",
   "ensembl": "ENSG00000147889",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": []
  },
  {
   "symbol": "SMAD4",
   "ensembl": "ENSG00000141646",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    }
   ]
  },
  {
   "symbol": "BRCA2",
   "ensembl": "ENSG00000139618",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "PALB2",
   "ensembl": "ENSG00000083093",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    }
   ]
  },
  {
   "symbol": "ATM",
   "ensembl": "ENSG00000149311",
   "n_drug_entries": 0,
   "n_distinct_drugs": 0,
   "drugs": {},
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    }
   ]
  },
  {
   "symbol": "EGFR",
   "ensembl": "ENSG00000146648",
   "n_drug_entries": 82,
   "n_distinct_drugs": 74,
   "drugs": {
    "ABIVERTINIB": "PHASE_3",
    "AC-480": "PHASE_2",
    "AEE-788": "PHASE_1_2",
    "AFATINIB": "APPROVAL",
    "AFATINIB DIMALEATE": "APPROVAL",
    "ALLITINIB": "PHASE_1",
    "AMIVANTAMAB": "APPROVAL",
    "AUMOLERTINIB": "APPROVAL",
    "AV-412": "PHASE_1",
    "AZD-3759": "PHASE_2_3",
    "AZD-4769": "PHASE_1",
    "BAFISONTAMAB": "PHASE_2",
    "BMS-690514": "PHASE_2",
    "BRIGATINIB": "APPROVAL",
    "CANERTINIB": "PHASE_2",
    "CEP-32496": "PHASE_1_2",
    "CETUXIMAB": "APPROVAL",
    "CETUXIMAB SAROTALOCAN": "APPROVAL",
    "CLN-081": "PHASE_3",
    "CUDC-101": "PHASE_1",
    "DACOMITINIB": "APPROVAL",
    "DEPATUXIZUMAB": "PHASE_2",
    "DEPATUXIZUMAB MAFODOTIN": "PHASE_3",
    "DULIGOTUZUMAB": "PHASE_2",
    "EPITINIB": "PHASE_1",
    "ERLOTINIB": "APPROVAL",
    "FALNIDAMOL": "PHASE_1",
    "FIRMONERTINIB": "PHASE_3",
    "FUTUXIMAB": "PHASE_3",
    "GC1118": "PHASE_2",
    "GEFITINIB": "APPROVAL",
    "ICOTINIB": "APPROVAL",
    "IMGATUZUMAB": "PHASE_2",
    "JNJ-26483327": "PHASE_1",
    "KBP5209": "PHASE_1",
    "LAPATINIB": "APPROVAL",
    "LAPATINIB DITOSYLATE": "APPROVAL",
    "LAZERTINIB": "APPROVAL",
    "LOSATUXIZUMAB VEDOTIN": "PHASE_1",
    "MAB-425": "UNKNOWN",
    "MATUZUMAB": "PHASE_2",
    "MAVELERTINIB": "PHASE_1_2",
    "MDX-447": "PHASE_1",
    "MOBOCERTINIB": "APPROVAL",
    "MODOTUXIMAB": "PHASE_2",
    "NAQUOTINIB": "PHASE_3",
    "NAZARTINIB": "PHASE_3",
    "NECITUMUMAB": "APPROVAL",
    "NERATINIB": "APPROVAL",
    "NIMOTUZUMAB": "APPROVAL",
    "OLMUTINIB": "APPROVAL",
    "OSIMERTINIB": "APPROVAL",
    "PANITUMUMAB": "APPROVAL",
    "PELITINIB": "PHASE_2",
    "PF-06459988": "PHASE_2",
    "PIMURUTAMAB": "PHASE_2_3",
    "PKI-166": "PHASE_2",
    "POZIOTINIB": "PHASE_3",
    "PYROTINIB": "PHASE_3",
    "RINDOPEPIMUT": "PHASE_3",
    "ROCILETINIB": "APPROVAL",
    "RUSERONTINIB": "PHASE_3",
    "S-222611": "PHASE_1",
    "SAPITINIB": "PHASE_2",
    "SIMOTINIB": "PHASE_1",
    "TAK-285": "PHASE_1",
    "TARLOXOTINIB": "PHASE_2",
    "TESEVATINIB": "PHASE_3",
    "THELIATINIB": "PHASE_1",
    "TOMUZOTUXIMAB": "PHASE_2",
    "TUXOBERTINIB": "PHASE_1_2",
    "VANDETANIB": "APPROVAL",
    "VARLITINIB": "PHASE_2_3",
    "ZALUTUMUMAB": "PHASE_3"
   },
   "approved": [
    "AFATINIB",
    "AFATINIB DIMALEATE",
    "AMIVANTAMAB",
    "AUMOLERTINIB",
    "BRIGATINIB",
    "CETUXIMAB",
    "CETUXIMAB SAROTALOCAN",
    "DACOMITINIB",
    "ERLOTINIB",
    "GEFITINIB",
    "ICOTINIB",
    "LAPATINIB",
    "LAPATINIB DITOSYLATE",
    "LAZERTINIB",
    "MOBOCERTINIB",
    "NECITUMUMAB",
    "NERATINIB",
    "NIMOTUZUMAB",
    "OLMUTINIB",
    "OSIMERTINIB",
    "PANITUMUMAB",
    "ROCILETINIB",
    "VANDETANIB"
   ],
   "n_approved": 23,
   "approved_for": {
    "AFATINIB": [
     "non-small cell lung carcinoma"
    ],
    "AFATINIB DIMALEATE": [
     "non-small cell lung carcinoma"
    ],
    "AMIVANTAMAB": [
     "non-small cell lung carcinoma"
    ],
    "AUMOLERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "BRIGATINIB": [
     "non-small cell lung carcinoma",
     "anaplastic large cell lymphoma"
    ],
    "CETUXIMAB": [
     "malignant tumor of neck",
     "squamous cell carcinoma",
     "colorectal adenocarcinoma",
     "colorectal carcinoma",
     "colorectal cancer",
     "head and neck neoplasm",
     "colorectal neoplasm"
    ],
    "CETUXIMAB SAROTALOCAN": [
     "head and neck cancer"
    ],
    "DACOMITINIB": [
     "non-small cell lung carcinoma"
    ],
    "ERLOTINIB": [
     "non-small cell lung carcinoma",
     "pancreatic neoplasm"
    ],
    "GEFITINIB": [
     "non-small cell lung carcinoma",
     "head and neck squamous cell carcinoma"
    ],
    "ICOTINIB": [],
    "LAPATINIB": [
     "breast cancer"
    ],
    "LAPATINIB DITOSYLATE": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "LAZERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "MOBOCERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "NECITUMUMAB": [
     "non-small cell lung carcinoma",
     "colorectal cancer",
     "non-small cell squamous lung carcinoma"
    ],
    "NERATINIB": [
     "breast cancer",
     "breast neoplasm",
     "breast carcinoma"
    ],
    "NIMOTUZUMAB": [
     "head and neck cancer"
    ],
    "OLMUTINIB": [],
    "OSIMERTINIB": [
     "non-small cell lung carcinoma"
    ],
    "PANITUMUMAB": [
     "colorectal cancer",
     "colorectal adenocarcinoma",
     "colorectal neoplasm"
    ],
    "ROCILETINIB": [],
    "VANDETANIB": [
     "thyroid gland carcinoma",
     "medullary thyroid gland carcinoma",
     "thyroid tumor"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Approved Drug"
    },
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Ligand"
    },
    {
     "modality": "SM",
     "bucket": "High-Quality Pocket"
    },
    {
     "modality": "SM",
     "bucket": "Druggable Family"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Literature"
    },
    {
     "modality": "PR",
     "bucket": "UniProt Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "PR",
     "bucket": "Half-life Data"
    },
    {
     "modality": "PR",
     "bucket": "Small Molecule Binder"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MSLN",
   "ensembl": "ENSG00000102854",
   "n_drug_entries": 5,
   "n_distinct_drugs": 5,
   "drugs": {
    "AMATUXIMAB": "PHASE_2",
    "ANETUMAB RAVTANSINE": "PHASE_2",
    "LMB-100": "PHASE_2",
    "RG-7600": "PHASE_1",
    "SS1(DSFV)-PE38": "PHASE_1_2"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "PR",
     "bucket": "Database Ubiquitination"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "CLDN18",
   "ensembl": "ENSG00000066405",
   "n_drug_entries": 1,
   "n_distinct_drugs": 1,
   "drugs": {
    "ZOLBETUXIMAB": "APPROVAL"
   },
   "approved": [
    "ZOLBETUXIMAB"
   ],
   "n_approved": 1,
   "approved_for": {
    "ZOLBETUXIMAB": [
     "gastric cancer",
     "neoplasm of esophagus",
     "gastric neoplasm",
     "gastric adenocarcinoma",
     "gastroesophageal junction adenocarcinoma"
    ]
   },
   "tractability": [
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "GO CC med conf"
    }
   ]
  },
  {
   "symbol": "CEACAM5",
   "ensembl": "ENSG00000105388",
   "n_drug_entries": 5,
   "n_distinct_drugs": 5,
   "drugs": {
    "ARCITUMOMAB": "APPROVAL",
    "LABETUZUMAB": "PHASE_2",
    "LABETUZUMAB GOVITECAN": "PHASE_2",
    "MEDI-565": "PHASE_1",
    "TUSAMITAMAB RAVTANSINE": "PHASE_3"
   },
   "approved": [
    "ARCITUMOMAB"
   ],
   "n_approved": 1,
   "approved_for": {
    "ARCITUMOMAB": [
     "breast cancer",
     "radiologic finding",
     "colorectal neoplasm"
    ]
   },
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "AB",
     "bucket": "Approved Drug"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  },
  {
   "symbol": "MUC1",
   "ensembl": "ENSG00000185499",
   "n_drug_entries": 12,
   "n_distinct_drugs": 12,
   "drugs": {
    "AR-20.5": "PHASE_1_2",
    "AS-1403": "PHASE_1",
    "CANTUZUMAB MERTANSINE": "PHASE_2",
    "CANTUZUMAB RAVTANSINE": "PHASE_2",
    "CMB-401": "UNKNOWN",
    "GATIPOTUZUMAB": "PHASE_2",
    "HUHMFG1": "PHASE_2",
    "M170": "PHASE_1",
    "NACOLOMAB TAFENATOX": "UNKNOWN",
    "SAR-566658": "PHASE_2",
    "SONTUZUMAB": "PHASE_2",
    "TECEMOTIDE": "PHASE_3"
   },
   "approved": [],
   "n_approved": 0,
   "approved_for": {},
   "tractability": [
    {
     "modality": "SM",
     "bucket": "Structure with Ligand"
    },
    {
     "modality": "SM",
     "bucket": "Med-Quality Pocket"
    },
    {
     "modality": "AB",
     "bucket": "Advanced Clinical"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc high conf"
    },
    {
     "modality": "AB",
     "bucket": "GO CC high conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt loc med conf"
    },
    {
     "modality": "AB",
     "bucket": "UniProt SigP or TMHMM"
    },
    {
     "modality": "AB",
     "bucket": "Human Protein Atlas loc"
    },
    {
     "modality": "OC",
     "bucket": "Advanced Clinical"
    }
   ]
  }
 ],
 "trials": {
  "by_antigen": {
   "mesothelin": {
    "n": 45,
    "n_observational": 3,
    "n_active": 12,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT05403554",
      "title": "A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers",
      "status": "RECRUITING",
      "last_update": "2024-10-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05779917",
      "title": "Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers",
      "status": "RECRUITING",
      "last_update": "2024-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06051695",
      "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06196294",
      "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers",
      "status": "RECRUITING",
      "last_update": "2024-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06756035",
      "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression",
      "status": "RECRUITING",
      "last_update": "2026-06-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760364",
      "title": "A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-04-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06885697",
      "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",
      "status": "RECRUITING",
      "last_update": "2026-08-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07066995",
      "title": "Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480928",
      "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07627711",
      "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00006981",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066651",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00325494",
      "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00570713",
      "title": "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00585845",
      "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment",
      "status": "TERMINATED",
      "last_update": "2009-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01413451",
      "title": "Amatuximab for High Mesothelin Cancers",
      "status": "TERMINATED",
      "last_update": "2019-12-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01417000",
      "title": "Safety and Efficacy of Combination Listeria/GVAX Immunotherapy in Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521325",
      "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01583686",
      "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-10-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01897415",
      "title": "Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02004262",
      "title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02159716",
      "title": "CART-meso in Mesothelin Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465983",
      "title": "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2019-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02485119",
      "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02580747",
      "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso",
      "status": "UNKNOWN",
      "last_update": "2015-10-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02706782",
      "title": "A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma",
      "status": "UNKNOWN",
      "last_update": "2016-03-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02810418",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959151",
      "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
      "status": "UNKNOWN",
      "last_update": "2016-11-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03006302",
      "title": "Epacadostat, Pembrolizumab, and CRS-207, With or Without CY/GVAX Pancreas in Patients With Metastatic Pancreas Cancer",
      "status": "COMPLETED",
      "last_update": "2024-10-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023722",
      "title": "Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03102320",
      "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03122106",
      "title": "Neoantigen DNA Vaccine in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy",
      "status": "TERMINATED",
      "last_update": "2023-10-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03190265",
      "title": "Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2024-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267173",
      "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
      "status": "UNKNOWN",
      "last_update": "2017-08-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03497819",
      "title": "Autologous CARTmeso/19 Against Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-04-13",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03507452",
      "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin",
      "status": "COMPLETED",
      "last_update": "2023-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03638193",
      "title": "Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-02-04",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816358",
      "title": "Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034238",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04809766",
      "title": "Mesothelin-Specific T-Cells (FH-TCR-T\u1d0ds\u029f\u0274) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2026-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05014776",
      "title": "Study of CRS-207, Pembrolizumab, Ipilimumab, and Tadalafil in Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05451849",
      "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer",
      "status": "TERMINATED",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06054308",
      "title": "Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study",
      "status": "WITHDRAWN",
      "last_update": "2024-08-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06256055",
      "title": "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-07-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 20,
     "n_observational": 1,
     "n_active": 8,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT05779917",
       "title": "Mesothelin/GPC3/GUCY2C-CAR-T Cells Against Cancers",
       "status": "RECRUITING",
       "last_update": "2024-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06051695",
       "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression",
       "status": "RECRUITING",
       "last_update": "2026-06-12",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06196294",
       "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers",
       "status": "RECRUITING",
       "last_update": "2024-06-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06885697",
       "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma",
       "status": "RECRUITING",
       "last_update": "2026-08-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07066995",
       "title": "Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer",
       "status": "RECRUITING",
       "last_update": "2025-07-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07480928",
       "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-03-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07627711",
       "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-06-04",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01583686",
       "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer",
       "status": "TERMINATED",
       "last_update": "2019-10-14",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT01897415",
       "title": "Autologous Redirected RNA Meso CAR T Cells for Pancreatic Cancer",
       "status": "COMPLETED",
       "last_update": "2017-09-19",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02159716",
       "title": "CART-meso in Mesothelin Expressing Cancers",
       "status": "COMPLETED",
       "last_update": "2025-06-29",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02465983",
       "title": "Pilot Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",
       "status": "TERMINATED",
       "last_update": "2019-12-16",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02580747",
       "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso",
       "status": "UNKNOWN",
       "last_update": "2015-10-20",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02706782",
       "title": "A Study of Mesothelin Redirected Autologous T Cells for Advanced Pancreatic Carcinoma",
       "status": "UNKNOWN",
       "last_update": "2016-03-11",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02959151",
       "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
       "status": "UNKNOWN",
       "last_update": "2016-11-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03267173",
       "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
       "status": "UNKNOWN",
       "last_update": "2017-08-30",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03497819",
       "title": "Autologous CARTmeso/19 Against Pancreatic Cancer",
       "status": "UNKNOWN",
       "last_update": "2018-04-13",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03638193",
       "title": "Study of Autologous T-cells in Patients With Metastatic Pancreatic Cancer",
       "status": "UNKNOWN",
       "last_update": "2021-02-04",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04809766",
       "title": "Mesothelin-Specific T-Cells (FH-TCR-T\u1d0ds\u029f\u0274) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",
       "status": "TERMINATED",
       "last_update": "2026-07-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06054308",
       "title": "Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a Feasibility Study",
       "status": "WITHDRAWN",
       "last_update": "2024-08-21",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "mesothelin",
     "MSLN",
     "anetumab",
     "amatuximab",
     "CRS-207",
     "LMB-100"
    ]
   },
   "CLDN18.2": {
    "n": 51,
    "n_observational": 2,
    "n_active": 35,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT05365581",
      "title": "A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05482893",
      "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05620732",
      "title": "Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T",
      "status": "RECRUITING",
      "last_update": "2022-11-22",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05911217",
      "title": "A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2024-05-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06005493",
      "title": "Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06219941",
      "title": "AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06602037",
      "title": "ImmunoPET Imaging of Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770439",
      "title": "IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07024615",
      "title": "A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07066098",
      "title": "A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)",
      "status": "RECRUITING",
      "last_update": "2025-08-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07066995",
      "title": "Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-07-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07079228",
      "title": "A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-09-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07416240",
      "title": "Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.",
      "status": "RECRUITING",
      "last_update": "2026-02-18",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07444541",
      "title": "ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480928",
      "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07488676",
      "title": "A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07595237",
      "title": "A IIT Study of 177Lu-DOTA-SNA040",
      "status": "RECRUITING",
      "last_update": "2026-08-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07597772",
      "title": "Preliminary Trial of SNA014 for Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-05-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07627711",
      "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03302403",
      "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors",
      "status": "UNKNOWN",
      "last_update": "2020-10-08",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816163",
      "title": "A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03890198",
      "title": "A Phase 1 Study of LCAR-C182A Cells in the Treatment of Advanced Gastric Cancer and Pancreatic Ductal Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2020-07-02",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04400383",
      "title": "Clinical Trial to Evaluate AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-05-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404595",
      "title": "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-01-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04581473",
      "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-06-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04683939",
      "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors",
      "status": "TERMINATED",
      "last_update": "2024-10-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04805307",
      "title": "Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy, Phase 1 Study of CMG901",
      "status": "COMPLETED",
      "last_update": "2025-02-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04966143",
      "title": "Clinical Study of LY011 in the Treatment of Advanced Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2021-07-19",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05009966",
      "title": "Study of SYSA1801 in the Treatment of Claudin( CLDN) 18.2 Positive Advanced Malignant Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2021-10-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05043987",
      "title": "Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers",
      "status": "WITHDRAWN",
      "last_update": "2023-09-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05156866",
      "title": "First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-01-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05159440",
      "title": "First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05181865",
      "title": "Phase 1/2a Study to Evaluate FL-301 in Patients With Advanced Solid Tumors",
      "status": "WITHDRAWN",
      "last_update": "2022-02-07",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05277987",
      "title": "An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects",
      "status": "UNKNOWN",
      "last_update": "2022-03-14",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05393986",
      "title": "Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-05-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05472857",
      "title": "Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression",
      "status": "UNKNOWN",
      "last_update": "2024-03-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05525286",
      "title": "Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2025-11-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05539430",
      "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05583201",
      "title": "NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-02-08",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06134960",
      "title": "NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2023-11-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06203613",
      "title": "Clinical Study of CLDN18.2 PET/CT for Noninvasive Diagnosis of Gastric and Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-02-16",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06396091",
      "title": "A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06464965",
      "title": "Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06646783",
      "title": "Phase IIT Trial of SNA014",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-10-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06792435",
      "title": "XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06921928",
      "title": "Study for AZD4360 in Participants With Advanced Solid Tumours",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07108504",
      "title": "Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-08-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07383922",
      "title": "A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07394205",
      "title": "Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-06",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07415525",
      "title": "IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-02-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 17,
     "n_observational": 0,
     "n_active": 11,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05620732",
       "title": "Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T",
       "status": "RECRUITING",
       "last_update": "2022-11-22",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07066995",
       "title": "Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer",
       "status": "RECRUITING",
       "last_update": "2025-07-15",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07416240",
       "title": "Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.",
       "status": "RECRUITING",
       "last_update": "2026-02-18",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07480928",
       "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-03-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07627711",
       "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-06-04",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03302403",
       "title": "Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors",
       "status": "UNKNOWN",
       "last_update": "2020-10-08",
       "phase": "NA",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04404595",
       "title": "Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-01-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04581473",
       "title": "Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CT041 Autologous CAR T-cell Injection",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-06-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05277987",
       "title": "An Evaluation Trial About Anti-claudin18.2 the Specificity of Chimeric Antigen Receptor T Cells in the Advanced Gastric / Esophagogastric Junction Adenocarcinoma and Pancreatic Cancer Subjects",
       "status": "UNKNOWN",
       "last_update": "2022-03-14",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05393986",
       "title": "Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2023-05-31",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05472857",
       "title": "Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression",
       "status": "UNKNOWN",
       "last_update": "2024-03-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05539430",
       "title": "Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-09-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05583201",
       "title": "NKG2D/CLDN18.2 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2023-02-08",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06134960",
       "title": "NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2023-11-18",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06464965",
       "title": "Clinical Study of Cord Blood-Derived CAR-NK Cells in Gastric Cancer and Pancreatic Cancer",
       "status": "COMPLETED",
       "last_update": "2026-07-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07394205",
       "title": "Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer",
       "status": "NOT_YET_RECRUITING",
       "last_update": "2026-02-06",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CLDN18.2",
     "claudin 18.2",
     "claudin-18.2",
     "Claudin18.2",
     "zolbetuximab",
     "osemitamab"
    ]
   },
   "CEA": {
    "n": 50,
    "n_observational": 5,
    "n_active": 13,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT05984810",
      "title": "NIR-Fluorescence Guided Surgical Resection of Neoadjuvant Treated Localized Pancreatic Cancer Using SGM-101",
      "status": "RECRUITING",
      "last_update": "2024-04-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06010862",
      "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06043466",
      "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06126406",
      "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2023-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06330441",
      "title": "Pancreatic Cancer Screening in a Population at High Risk",
      "status": "RECRUITING",
      "last_update": "2026-04-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06549725",
      "title": "Clinical Performance of Medical Device Software \"Lipidica 1.0\" for Processing Data Generated by Lipidomic Analysis in Pancreatic Cancer Screening",
      "status": "RECRUITING",
      "last_update": "2026-04-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06821048",
      "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-01-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07179692",
      "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-10-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003125",
      "title": "Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors",
      "status": "COMPLETED",
      "last_update": "2011-03-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003434",
      "title": "Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2014-02-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004604",
      "title": "Biological Therapy in Treating Patients With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00012246",
      "title": "Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract",
      "status": "TERMINATED",
      "last_update": "2013-05-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00027534",
      "title": "Vaccine Therapy in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00028496",
      "title": "Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00041639",
      "title": "Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00128622",
      "title": "Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-12",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00203892",
      "title": "Study of CAP1-6D in Patients With Locally Advanced or Surgically Resected Pancreatic Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2014-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00529984",
      "title": "A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies",
      "status": "COMPLETED",
      "last_update": "2012-07-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00669734",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01212887",
      "title": "Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer",
      "status": "TERMINATED",
      "last_update": "2012-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01333124",
      "title": "Preoperative Chemoradiotherapy With Gemcitabine for Resectable Pancreatic Carcinoma",
      "status": "TERMINATED",
      "last_update": "2020-04-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02293954",
      "title": "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-14",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02349724",
      "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-04-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02416466",
      "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases",
      "status": "COMPLETED",
      "last_update": "2019-03-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02817308",
      "title": "Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas",
      "status": "UNKNOWN",
      "last_update": "2018-08-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02850536",
      "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer",
      "status": "COMPLETED",
      "last_update": "2021-10-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02959151",
      "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
      "status": "UNKNOWN",
      "last_update": "2016-11-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03127098",
      "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer",
      "status": "TERMINATED",
      "last_update": "2024-08-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03136406",
      "title": "QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",
      "status": "TERMINATED",
      "last_update": "2024-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267173",
      "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
      "status": "UNKNOWN",
      "last_update": "2017-08-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03329248",
      "title": "QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",
      "status": "TERMINATED",
      "last_update": "2024-12-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03387098",
      "title": "QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy",
      "status": "TERMINATED",
      "last_update": "2024-05-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563144",
      "title": "QUILT-3.088: NANT Pancreatic Cancer Vaccine",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03586869",
      "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03682744",
      "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",
      "status": "WITHDRAWN",
      "last_update": "2022-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03818165",
      "title": "Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases",
      "status": "TERMINATED",
      "last_update": "2023-01-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03820531",
      "title": "DNA-mutation Analysis in Cyst Fluid of Suspected Intraductal Papillary Mucinous Neoplasia of the Pancreas",
      "status": "COMPLETED",
      "last_update": "2022-12-20",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04037241",
      "title": "Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases",
      "status": "WITHDRAWN",
      "last_update": "2022-04-01",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04348643",
      "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer",
      "status": "WITHDRAWN",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04404101",
      "title": "Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies",
      "status": "UNKNOWN",
      "last_update": "2024-05-21",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04659603",
      "title": "Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04920019",
      "title": "Opioid Sparing Effect of Thoracic Epidural Analgesia for Open Upper Abdominal Surgery",
      "status": "COMPLETED",
      "last_update": "2023-08-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05415475",
      "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05538195",
      "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05726864",
      "title": "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05736731",
      "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06006390",
      "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-08-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06241352",
      "title": "Statin Addition to Chemotherapy for Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06395337",
      "title": "Multimodal Imaging in Rectal Cancer & Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06710132",
      "title": "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 18,
     "n_observational": 0,
     "n_active": 6,
     "n_withdrawn": 3,
     "trials": [
      {
       "nct": "NCT06010862",
       "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-11-08",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06043466",
       "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-09-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06126406",
       "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2023-11-13",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06821048",
       "title": "Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-01-23",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07179692",
       "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2025-10-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02349724",
       "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer",
       "status": "UNKNOWN",
       "last_update": "2017-04-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02416466",
       "title": "CAR-T Hepatic Artery Infusions and Sir-Spheres for Liver Metastases",
       "status": "COMPLETED",
       "last_update": "2019-03-26",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02850536",
       "title": "CAR-T Hepatic Artery Infusions or Pancreatic Venous Infusions for CEA-Expressing Liver Metastases or Pancreas Cancer",
       "status": "COMPLETED",
       "last_update": "2021-10-21",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02959151",
       "title": "A Study of Chimeric Antigen Receptor T Cells Combined With Interventional Therapy in Advanced Liver Malignancy",
       "status": "UNKNOWN",
       "last_update": "2016-11-08",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03267173",
       "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
       "status": "UNKNOWN",
       "last_update": "2017-08-30",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03682744",
       "title": "CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)",
       "status": "WITHDRAWN",
       "last_update": "2022-04-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03818165",
       "title": "Phase 1b Study of CAR2Anti-CEA CAR-T Cell Hepatic Infusions for Pancreatic Carcinoma Patients With CEA+ Liver Metastases",
       "status": "TERMINATED",
       "last_update": "2023-01-17",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04037241",
       "title": "Study of Anti-CEA CAR-T + Chemotherapy VS Chemotherapy Alone in Patients With CEA+Pancreatic Cancer & Liver Metastases",
       "status": "WITHDRAWN",
       "last_update": "2022-04-01",
       "phase": "PHASE2/PHASE3",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04348643",
       "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer",
       "status": "WITHDRAWN",
       "last_update": "2026-07-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05415475",
       "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2026-07-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05538195",
       "title": "Safety and Efficacy of CEA-targeted CAR-T for CEA-positive Advanced Malignant Solid Tumors",
       "status": "COMPLETED",
       "last_update": "2026-07-10",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05736731",
       "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2025-04-25",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06006390",
       "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors",
       "status": "UNKNOWN",
       "last_update": "2024-08-09",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "CEA",
     "CEACAM5",
     "carcinoembryonic antigen",
     "tusamitamab",
     "labetuzumab"
    ]
   },
   "MUC1": {
    "n": 19,
    "n_observational": 0,
    "n_active": 7,
    "n_withdrawn": 3,
    "trials": [
     {
      "nct": "NCT07166601",
      "title": "M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07480928",
      "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-03-18",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07627711",
      "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-06-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00008099",
      "title": "Vaccine Therapy in Treating Patients With Resected or Locally Advanced Unresectable Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-01-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00597129",
      "title": "Safety and Efficacy Study of 90Y-hPAM4 at Different Doses",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00603863",
      "title": "Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00669734",
      "title": "Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02132403",
      "title": "(PM-01) IMPRIME PGG\u00ae With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2015-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02310971",
      "title": "Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas",
      "status": "WITHDRAWN",
      "last_update": "2015-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02587689",
      "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02839954",
      "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
      "status": "UNKNOWN",
      "last_update": "2016-12-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03114631",
      "title": "Dendritic Cell Immunotherapy for the Patients With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2019-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267173",
      "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
      "status": "UNKNOWN",
      "last_update": "2017-08-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03509298",
      "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-10-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563144",
      "title": "QUILT-3.088: NANT Pancreatic Cancer Vaccine",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03586869",
      "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05239143",
      "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-02-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07670312",
      "title": "Evaluation of XYA02 in Patients With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 0,
     "n_active": 4,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT07480928",
       "title": "Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-03-18",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07627711",
       "title": "Dual-Target CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma",
       "status": "RECRUITING",
       "last_update": "2026-06-04",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02587689",
       "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-05",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02839954",
       "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor",
       "status": "UNKNOWN",
       "last_update": "2016-12-06",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03267173",
       "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
       "status": "UNKNOWN",
       "last_update": "2017-08-30",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05239143",
       "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors",
       "status": "ACTIVE_NOT_RECRUITING",
       "last_update": "2026-02-09",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "MUC1",
     "mucin-1",
     "mucin 1",
     "TAB004"
    ]
   },
   "PSCA": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02092948",
      "title": "Phase I Study to evaluate124I-A11 PSCA Minibody in Patients With Metastatic Prostate, Bladder and Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267173",
      "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
      "status": "UNKNOWN",
      "last_update": "2017-08-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07608627",
      "title": "64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 1,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT03267173",
       "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
       "status": "UNKNOWN",
       "last_update": "2017-08-30",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "PSCA",
     "prostate stem cell antigen"
    ]
   },
   "TROP2": {
    "n": 12,
    "n_observational": 0,
    "n_active": 9,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05417594",
      "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05941507",
      "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-09-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969041",
      "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06065371",
      "title": "Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy",
      "status": "RECRUITING",
      "last_update": "2025-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06428409",
      "title": "A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06602037",
      "title": "ImmunoPET Imaging of Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-29",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01631552",
      "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05922930",
      "title": "Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-07-30",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07377526",
      "title": "TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer",
      "status": "SUSPENDED",
      "last_update": "2026-07-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07561463",
      "title": "Sacituzumab Tirumotecan for Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 2,
     "n_observational": 0,
     "n_active": 0,
     "n_withdrawn": 0,
     "trials": [
      {
       "nct": "NCT05922930",
       "title": "Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer",
       "status": "SUSPENDED",
       "last_update": "2026-07-30",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07377526",
       "title": "TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer",
       "status": "SUSPENDED",
       "last_update": "2026-07-31",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "TROP2",
     "TROP-2",
     "TACSTD2",
     "sacituzumab",
     "datopotamab"
    ]
   },
   "HER2": {
    "n": 67,
    "n_observational": 5,
    "n_active": 30,
    "n_withdrawn": 4,
    "trials": [
     {
      "nct": "NCT03740256",
      "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-02-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04150042",
      "title": "SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04389632",
      "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05372614",
      "title": "Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05417594",
      "title": "Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05482893",
      "title": "Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or ICI, for the Treatment of Patients With Advanced Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)",
      "status": "RECRUITING",
      "last_update": "2026-07-09",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05786716",
      "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations",
      "status": "RECRUITING",
      "last_update": "2025-12-02",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05969041",
      "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors",
      "status": "RECRUITING",
      "last_update": "2024-01-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06084481",
      "title": "Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06330064",
      "title": "A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06500052",
      "title": "A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-09-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06695845",
      "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06715839",
      "title": "Target-specific immunoPET Imaging of Digestive System Carcinoma",
      "status": "RECRUITING",
      "last_update": "2025-12-31",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06760819",
      "title": "A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06813079",
      "title": "Using Tumor Models to Determine Treatments",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06907043",
      "title": "A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.",
      "status": "RECRUITING",
      "last_update": "2025-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07523529",
      "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07630961",
      "title": "Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00003797",
      "title": "Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas",
      "status": "UNKNOWN",
      "last_update": "2013-12-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004074",
      "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu",
      "status": "COMPLETED",
      "last_update": "2013-02-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005842",
      "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-02-11",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005926",
      "title": "Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas",
      "status": "COMPLETED",
      "last_update": "2008-03-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00031681",
      "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)",
      "status": "COMPLETED",
      "last_update": "2013-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00034281",
      "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2",
      "status": "COMPLETED",
      "last_update": "2012-02-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00862524",
      "title": "A Study of ARRY-334543 and Gemcitabine in Patients With Advanced Cancer and Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-10-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923299",
      "title": "Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00959946",
      "title": "Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer",
      "status": "TERMINATED",
      "last_update": "2013-02-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01384253",
      "title": "Safety Study of \u00b2\u00b9\u00b2Pb-TCMC-Trastuzumab Radio Immunotherapy",
      "status": "COMPLETED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01576666",
      "title": "Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-12-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02403271",
      "title": "A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-01-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02451553",
      "title": "Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02662348",
      "title": "T Cell Mediated Adaptive Therapy for Her2-positive Neoplasms of Digestive System",
      "status": "UNKNOWN",
      "last_update": "2016-01-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02713984",
      "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer",
      "status": "WITHDRAWN",
      "last_update": "2020-03-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02791334",
      "title": "A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-09-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02912949",
      "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-04-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02999672",
      "title": "A Study to Determine Best Tumor Response With Trastuzumab Emtansine in Human Epidermal Growth Factor Receptor 2 (HER2) Overexpressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2019-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03267173",
      "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
      "status": "UNKNOWN",
      "last_update": "2017-08-30",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03425773",
      "title": "Safety and Tolerability Evaluation Study of BVAC-B in Patients With HER2/Neu(Human Epithelial Growth Factor Receptor 2) Positive Gastric Cancer After Failure to Standard Care",
      "status": "COMPLETED",
      "last_update": "2020-02-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03563144",
      "title": "QUILT-3.088: NANT Pancreatic Cancer Vaccine",
      "status": "WITHDRAWN",
      "last_update": "2025-02-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03586869",
      "title": "QUILT-3.080: NANT Pancreatic Cancer Vaccine",
      "status": "TERMINATED",
      "last_update": "2024-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03602079",
      "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
      "status": "COMPLETED",
      "last_update": "2023-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03924466",
      "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients",
      "status": "UNKNOWN",
      "last_update": "2024-02-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04025216",
      "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers",
      "status": "TERMINATED",
      "last_update": "2024-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04042480",
      "title": "A Study of SGN-CD228A in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-03-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04182516",
      "title": "Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2024-09-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04247126",
      "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-10-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04319757",
      "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-12-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04336098",
      "title": "Study of SRF617 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2024-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04482309",
      "title": "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04584008",
      "title": "Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-10-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04639219",
      "title": "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04644068",
      "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04660929",
      "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2024-12-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04665921",
      "title": "A Study of SGN-STNV in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-02-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05143970",
      "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-06-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05238831",
      "title": "SMMART Adaptive Clinical Treatment (ACT) Trial",
      "status": "WITHDRAWN",
      "last_update": "2024-01-23",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05933265",
      "title": "Study of LP-184 in Patients With Advanced Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06233864",
      "title": "A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-04-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07619521",
      "title": "Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631871",
      "title": "An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07631884",
      "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07802418",
      "title": "Molecularly Tailored Therapy in Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 4,
     "n_observational": 0,
     "n_active": 1,
     "n_withdrawn": 1,
     "trials": [
      {
       "nct": "NCT07523529",
       "title": "Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-04-13",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT02713984",
       "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer",
       "status": "WITHDRAWN",
       "last_update": "2020-03-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03267173",
       "title": "Evaluate the Safety and Efficacy of CAR-T in the Treatment of Pancreatic Cancer.",
       "status": "UNKNOWN",
       "last_update": "2017-08-30",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT04025216",
       "title": "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers",
       "status": "TERMINATED",
       "last_update": "2024-01-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "HER2",
     "ERBB2",
     "trastuzumab"
    ]
   },
   "KRAS G12D": {
    "n": 85,
    "n_observational": 2,
    "n_active": 59,
    "n_withdrawn": 5,
    "trials": [
     {
      "nct": "NCT03608631",
      "title": "iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04146298",
      "title": "Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05013216",
      "title": "Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05379985",
      "title": "Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",
      "status": "RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06040541",
      "title": "Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06128551",
      "title": "Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06179160",
      "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06218914",
      "title": "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06385925",
      "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06403735",
      "title": "A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2024-05-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06411691",
      "title": "KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-31",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06496373",
      "title": "Clinical Study of mRNA Vaccine Combined With PD-1 Inhibitor as Adjuvant Therapy for Postoperative Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-11-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06577532",
      "title": "Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2025-05-21",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586515",
      "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770452",
      "title": "HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06782932",
      "title": "Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2025-12-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06895031",
      "title": "Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS",
      "status": "RECRUITING",
      "last_update": "2026-03-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06922591",
      "title": "Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients",
      "status": "RECRUITING",
      "last_update": "2026-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06959615",
      "title": "A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration",
      "status": "RECRUITING",
      "last_update": "2026-01-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06973564",
      "title": "JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration",
      "status": "RECRUITING",
      "last_update": "2026-01-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094204",
      "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07148128",
      "title": "Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.",
      "status": "RECRUITING",
      "last_update": "2026-01-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07232875",
      "title": "HRS 4642 Injection Combined With AG Versus Placebo Combined With AG Therapy in First-Line Advanced or Metastatic Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-07-15",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07240766",
      "title": "HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07262567",
      "title": "Phase III Study to Compare GFH375 and Chemotherapy in Patients With KRAS G12D-Mutant Metastatic Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-14",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07349537",
      "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07409272",
      "title": "A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07438106",
      "title": "A Phase II Study of HRS-4642 Combined With AG (Nab-paclitaxel and Gemcitabine) as Conversion Therapy for Locally Advanced Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-08-12",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07483983",
      "title": "Study Investigating ASP3082 in Patients With Metastatic/Locally Advanced Non-small-cell Lung Cancer (NSCLC) and Pancreatic Ductal Adenocarcinoma (PDAC), With Biomarker Analysis to Characterize Response/Resistance",
      "status": "RECRUITING",
      "last_update": "2026-08-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07522073",
      "title": "A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07594067",
      "title": "TCR1188-ABC Cells in KRAS-mutated Cancers",
      "status": "RECRUITING",
      "last_update": "2026-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07610798",
      "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced Solid Tumors Harboring KRAS G12D Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07621718",
      "title": "Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",
      "status": "RECRUITING",
      "last_update": "2026-09-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07629960",
      "title": "A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07640295",
      "title": "Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations",
      "status": "RECRUITING",
      "last_update": "2026-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07644559",
      "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07671339",
      "title": "A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-26",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07805954",
      "title": "Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma",
      "status": "RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00841191",
      "title": "A Safety, Efficacy and Pharmacokinetic Study of Siltuximab (CNTO 328) in Participants With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2014-05-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00955773",
      "title": "A Study of the GSK MEK Inhibitor GSK1120212 and Everolimus in Cancer Subjects",
      "status": "COMPLETED",
      "last_update": "2017-11-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01562899",
      "title": "A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-12-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02703571",
      "title": "Study of Safety and Efficacy of Ribociclib and Trametinib in Patients With Metastatic or Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2020-12-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03415126",
      "title": "A Study of ASN007 in Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2020-07-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03592888",
      "title": "DC Vaccine in Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-06-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03637491",
      "title": "A Study of Avelumab, Binimetinib and Talazoparib in Patients With Locally Advanced or Metastatic RAS-mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2022-01-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03745326",
      "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients",
      "status": "TERMINATED",
      "last_update": "2026-05-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03875820",
      "title": "Phase I Trial of Defactinib and VS-6766.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-03-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03948763",
      "title": "A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
      "status": "TERMINATED",
      "last_update": "2025-01-28",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04117087",
      "title": "Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-27",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04132505",
      "title": "Binimetinib and Hydroxychloroquine in Treating Patients With KRAS Mutant Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04560270",
      "title": "CIrculating Tumor DNA for Monitoring Response to First Line Chemotherapy in Unresectable PANcreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-09-23",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04853017",
      "title": "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-09-05",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04916236",
      "title": "Combination Therapy of RMC-4630 and LY3214996 in Metastatic KRAS Mutant Cancers",
      "status": "TERMINATED",
      "last_update": "2025-01-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04956640",
      "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05315180",
      "title": "A Phase 1\uff0cOpen-label Study of BPI-421286 in Subjects With Advanced Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2022-04-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05438667",
      "title": "TCR-T Cell Therapy on Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-09-01",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05462717",
      "title": "Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05585320",
      "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-09-02",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05634525",
      "title": "Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients",
      "status": "WITHDRAWN",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05726864",
      "title": "A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05737706",
      "title": "Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation",
      "status": "TERMINATED",
      "last_update": "2025-04-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06194877",
      "title": "A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06208124",
      "title": "A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2025-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06364696",
      "title": "A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2026-07-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06487377",
      "title": "IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations",
      "status": "WITHDRAWN",
      "last_update": "2026-09-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607185",
      "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06690281",
      "title": "A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies",
      "status": "WITHDRAWN",
      "last_update": "2025-09-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06707896",
      "title": "TCR1020-CD8 T Cells in KRAS-mutated Cancers",
      "status": "WITHDRAWN",
      "last_update": "2025-06-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06818812",
      "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07014878",
      "title": "A Study of DCTY1102 Injection in Participants With Advanced Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07023731",
      "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07026916",
      "title": "A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer",
      "status": "WITHDRAWN",
      "last_update": "2025-11-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07619521",
      "title": "Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a, for Advanced Pancreatic Ductal Adenocarcinoma",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07624214",
      "title": "Study of LT-010391 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07656376",
      "title": "Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer With KRAS G12D Mutation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-06-18",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07689539",
      "title": "Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-08",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07784374",
      "title": "A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 Monotherapy in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ],
    "cell_therapy": {
     "n": 7,
     "n_observational": 1,
     "n_active": 3,
     "n_withdrawn": 2,
     "trials": [
      {
       "nct": "NCT04146298",
       "title": "Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer",
       "status": "RECRUITING",
       "last_update": "2025-12-24",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06218914",
       "title": "Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors",
       "status": "RECRUITING",
       "last_update": "2026-08-24",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT07594067",
       "title": "TCR1188-ABC Cells in KRAS-mutated Cancers",
       "status": "RECRUITING",
       "last_update": "2026-08-06",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT03745326",
       "title": "Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients",
       "status": "TERMINATED",
       "last_update": "2026-05-19",
       "phase": "PHASE1/PHASE2",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT05438667",
       "title": "TCR-T Cell Therapy on Advanced Solid Tumors",
       "status": "TERMINATED",
       "last_update": "2026-09-01",
       "phase": "EARLY_PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06487377",
       "title": "IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations",
       "status": "WITHDRAWN",
       "last_update": "2026-09-02",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      },
      {
       "nct": "NCT06707896",
       "title": "TCR1020-CD8 T Cells in KRAS-mutated Cancers",
       "status": "WITHDRAWN",
       "last_update": "2025-06-25",
       "phase": "PHASE1",
       "study_type": "INTERVENTIONAL"
      }
     ]
    },
    "synonyms_searched": [
     "KRAS G12D",
     "G12D",
     "mutant KRAS",
     "mRNA-5671",
     "ELI-002"
    ]
   }
  },
  "by_drug": {
   "ADAGRASIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT06026410",
      "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-06-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04330664",
      "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)",
      "status": "COMPLETED",
      "last_update": "2025-04-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04975256",
      "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)",
      "status": "TERMINATED",
      "last_update": "2024-12-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05634525",
      "title": "Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients",
      "status": "WITHDRAWN",
      "last_update": "2025-07-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06130254",
      "title": "Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers",
      "status": "TERMINATED",
      "last_update": "2026-04-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01728818",
      "title": "Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours",
      "status": "UNKNOWN",
      "last_update": "2017-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02451553",
      "title": "Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02975141",
      "title": "Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AFATINIB DIMALEATE": {
    "n": 7,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT01728818",
      "title": "Afatinib as Cancer Therapy for Exocrine Pancreatic Tumours",
      "status": "UNKNOWN",
      "last_update": "2017-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02450656",
      "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-27",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02451553",
      "title": "Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",
      "status": "COMPLETED",
      "last_update": "2022-06-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02975141",
      "title": "Afatinib and Gemcitabine/Nab-paclitaxel in Metastatic Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2018-08-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMATUXIMAB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00325494",
      "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-07-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00570713",
      "title": "An Efficacy Study of MORAb-009 in Subjects With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01413451",
      "title": "Amatuximab for High Mesothelin Cancers",
      "status": "TERMINATED",
      "last_update": "2019-12-17",
      "phase": "EARLY_PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01521325",
      "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers",
      "status": "COMPLETED",
      "last_update": "2016-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "AMIVANTAMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ANETUMAB RAVTANSINE": {
    "n": 4,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02485119",
      "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03023722",
      "title": "Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-10-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03102320",
      "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-06-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03816358",
      "title": "Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "BRIGATINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06813079",
      "title": "Using Tumor Models to Determine Treatments",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CANTUZUMAB RAVTANSINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00352131",
      "title": "Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2010-03-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CETUXIMAB": {
    "n": 58,
    "n_observational": 0,
    "n_active": 20,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT06179160",
      "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06385925",
      "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-04-24",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06445062",
      "title": "Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06586515",
      "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-08-24",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06835569",
      "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-06-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06917079",
      "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer",
      "status": "RECRUITING",
      "last_update": "2026-06-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07020221",
      "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-04-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07223047",
      "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies",
      "status": "RECRUITING",
      "last_update": "2026-05-28",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07300150",
      "title": "A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07349537",
      "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07644559",
      "title": "A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00005591",
      "title": "Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas",
      "status": "WITHDRAWN",
      "last_update": "2013-12-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00042939",
      "title": "Irinotecan and Docetaxel With or Without Cetuximab in Treating Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2023-07-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00075686",
      "title": "S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer",
      "status": "COMPLETED",
      "last_update": "2015-11-17",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091026",
      "title": "Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00225784",
      "title": "Cetuximab, Radiotherapy and Twice Weekly Gemcitabine to Treat Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-07-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00276744",
      "title": "Individualized Drug Treatment for Treating Patients With Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00305760",
      "title": "Vaccine Therapy, Cyclophosphamide, and Cetuximab in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-02-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00305877",
      "title": "Bevacizumab or Cetuximab And Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Pacreatic Cancer That Has Been Completely Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2014-05-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00326911",
      "title": "Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2011-05-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00338039",
      "title": "Induction Cetuximab (IM-C225), Gemcitabine, and Oxaliplatin in Pancreatic Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2013-03-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00383149",
      "title": "A Phase II, Trial of Ixabepilone Plus Cetuximab as First Line Therapy for Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-03-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00395252",
      "title": "Safety and Efficacy Therapy of Gemcitabine and Erbitux\u00ae to R0 or R1 Resected Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-10-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00408564",
      "title": "Cetuximab, Gemcitabine, and Oxaliplatin Followed By Surgery or External-Beam Radiation Therapy and Capecitabine in Treating Patients With Locally Advanced, Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2018-07-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00424827",
      "title": "A Trial of Chemo & Radiation Therapy for Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-06-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00448838",
      "title": "Cetuximab, Gemcitabine, and Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-12-15",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00467116",
      "title": "PhI Study of Erbitux & Gemcitabine w/Radiation Therapy for Locally Adv. Pancreas Ca",
      "status": "COMPLETED",
      "last_update": "2012-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536614",
      "title": "Gemcitabine/Cisplatin +/-Cetuximab in Patients With Locally Advanced or Metastatic EGFR-Positive Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2007-09-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00599833",
      "title": "Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2013-06-26",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00622674",
      "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2017-12-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00871169",
      "title": "Combination of Irinotecan, Oxaliplatin and Cetuximab for Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00923299",
      "title": "Cetuximab and Trastuzumab in Treating Patients With Metastatic Pancreatic Cancer That Progressed After Previous Treatment With Gemcitabine",
      "status": "COMPLETED",
      "last_update": "2019-04-16",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01042028",
      "title": "A Randomised Trial With Irinotecan, Cetuximab and Everolimus (ICE)Compared to Capecitabine and Oxaliplatin (CapOx) for Patients With Gemcitabin Resistant Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2015-10-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01050426",
      "title": "A Clinical Study of UFT/Leucovorin, Radiotherapy With or Without Cetuximab Following Induction Gemcitabine Plus Capecitabine in Patients With Locally Advanced Pancreatic Cancer (PERU)",
      "status": "TERMINATED",
      "last_update": "2016-10-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01077986",
      "title": "Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-21",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01420874",
      "title": "Anti-CD3 x Anti-Erbitux\u00ae Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)",
      "status": "COMPLETED",
      "last_update": "2023-05-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02241187",
      "title": "Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection",
      "status": "COMPLETED",
      "last_update": "2017-09-27",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02736578",
      "title": "Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery",
      "status": "TERMINATED",
      "last_update": "2019-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03009058",
      "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer",
      "status": "TERMINATED",
      "last_update": "2024-11-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03319459",
      "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2021-11-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03785249",
      "title": "Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04464967",
      "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers",
      "status": "WITHDRAWN",
      "last_update": "2021-05-12",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04956640",
      "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-05-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05039177",
      "title": "A Study of ERAS-007 in Patients With Advanced Gastrointestinal Malignancies",
      "status": "COMPLETED",
      "last_update": "2026-03-25",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05395052",
      "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2023-09-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06024174",
      "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-07-22",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06447662",
      "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06585488",
      "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification",
      "status": "TERMINATED",
      "last_update": "2026-07-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06599502",
      "title": "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation",
      "status": "TERMINATED",
      "last_update": "2026-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06607185",
      "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06704724",
      "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.",
      "status": "TERMINATED",
      "last_update": "2026-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06818812",
      "title": "A Study to Evaluate INCB186748 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07302841",
      "title": "Tunlametinib + AG + Cetuximab \u03b2 as First-Line Therapy for Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07446270",
      "title": "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07678593",
      "title": "A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-10",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07698613",
      "title": "EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "CETUXIMAB SAROTALOCAN": {
    "n": 1,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT07698613",
      "title": "EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-07-13",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "DACOMITINIB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ERLOTINIB": {
    "n": 89,
    "n_observational": 2,
    "n_active": 4,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT06483555",
      "title": "Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel",
      "status": "RECRUITING",
      "last_update": "2026-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00026338",
      "title": "Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-04-02",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00030498",
      "title": "Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction",
      "status": "COMPLETED",
      "last_update": "2013-01-16",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00033241",
      "title": "Erlotinib Combined With Gemcitabine in Treating Patients With Newly Diagnosed Locally Advanced or Metastatic Pancreatic Cancer or Other Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00040183",
      "title": "OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00047307",
      "title": "Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00063947",
      "title": "Erlotinib, Gemcitabine, and Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00091026",
      "title": "Bevacizumab and Gemcitabine Combined With Either Cetuximab or Erlotinib in Treating Patients With Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101348",
      "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer",
      "status": "COMPLETED",
      "last_update": "2014-06-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00125021",
      "title": "Tarceva and Capecitabine for Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2009-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00243854",
      "title": "Pilot Study Using Neoadj Chemo-Rad & EGFR-tyrosine Kinase Inhibitor for Potentially Resectable Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-03-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00260364",
      "title": "Combining Erlotinib Plus Bevacizumab and Gemcitabine Plus Capecitabine to Treat Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-10-14",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00266097",
      "title": "Oxaliplatin, Gemcitabine, Erlotinib, and Radiation Therapy in Treating Patients With Unresectable and/or Metastatic Pancreatic Cancer or Biliary Tract Cancer",
      "status": "COMPLETED",
      "last_update": "2012-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00276744",
      "title": "Individualized Drug Treatment for Treating Patients With Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2018-10-24",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00313560",
      "title": "ChemoRT With Adjuvant Chemo in Pancreatic Cancer (TARCEVA)",
      "status": "COMPLETED",
      "last_update": "2020-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00336700",
      "title": "A Phase II Study of Gemcitabine and Erlotinib As Adjuvant Therapy In Patients With Resected Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2016-09-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00365144",
      "title": "Bevacizumab and Erlotinib in Treating Patients With Metastatic Pancreatic Cancer That Did Not Respond to Previous Treatment With Gemcitabine",
      "status": "COMPLETED",
      "last_update": "2018-01-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00366457",
      "title": "Gemcitabine, Bevacizumab and Erlotinib in Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-05-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00376948",
      "title": "Genistein, Gemcitabine, and Erlotinib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-03-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00397384",
      "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer",
      "status": "COMPLETED",
      "last_update": "2015-09-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00440167",
      "title": "Capecitabine/Erlotinib Followed of Gemcitabine Versus Gemcitabine/Erlotinib Followed of Capecitabine",
      "status": "UNKNOWN",
      "last_update": "2012-07-09",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00461708",
      "title": "A Study of Tarceva (Erlotinib) in Combination With Gemcitabine in Unresectable and/or Metastatic Cancer of the Pancreas: Relationship Between Skin Toxicity and Survival",
      "status": "COMPLETED",
      "last_update": "2015-10-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00470535",
      "title": "Erlotinib in Treating Patients With Stage III or Stage IV Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2017-02-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00480584",
      "title": "A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00482625",
      "title": "Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",
      "status": "TERMINATED",
      "last_update": "2014-10-16",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00497224",
      "title": "Phase II Trial of Erlotinib in Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2019-05-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00536770",
      "title": "A Study of Gemcitabine \u00b1 Erlotinib and DN-101 Versus Gemcitabine \u00b1 Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer",
      "status": "SUSPENDED",
      "last_update": "2007-11-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00550836",
      "title": "Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00564720",
      "title": "Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2013-02-15",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00565487",
      "title": "Combination Study of Capecitabine and Erlotinib Concurrent With Radiotherapy for Non-Operable Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00614653",
      "title": "Bevacizumab, Erlotinib and Capecitabine for Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00617708",
      "title": "S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery",
      "status": "COMPLETED",
      "last_update": "2022-02-08",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00634725",
      "title": "Gemcitabine With or Without Capecitabine and/or Radiation Therapy or Gemcitabine With or Without Erlotinib in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2015-12-11",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00636883",
      "title": "Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-na\u00efve Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2014-01-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00640978",
      "title": "Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-07-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00642733",
      "title": "A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2016-08-24",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00652366",
      "title": "A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-02-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00674973",
      "title": "A Biomarker Identification Trial of Tarceva (Erlotinib) in Patients With Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00696696",
      "title": "Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2016-06-30",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00709826",
      "title": "APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00728000",
      "title": "Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma",
      "status": "WITHDRAWN",
      "last_update": "2019-11-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00733746",
      "title": "Gemcitabine and Erlotinib Before and After Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2019-10-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00735306",
      "title": "Phase I/II Trial of Radiation, Avastin and Tarceva for Pancreatic Adenocarcinoma",
      "status": "COMPLETED",
      "last_update": "2015-06-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00739453",
      "title": "A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva\u00ae)",
      "status": "COMPLETED",
      "last_update": "2024-11-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00761345",
      "title": "Study of Low-Dose Fractionated Radiotherapy in Patients With Locally Advanced Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-03-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00766636",
      "title": "Preoperative Chemotherapy (Gemcitabine and Erlotinib) With or Without Radiation Therapy",
      "status": "TERMINATED",
      "last_update": "2016-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00769483",
      "title": "MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-09-03",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00810719",
      "title": "Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2018-01-10",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00837876",
      "title": "Sorafenib and Erlotinib in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2014-06-25",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00841035",
      "title": "7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients",
      "status": "TERMINATED",
      "last_update": "2017-05-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00843531",
      "title": "RAD001 and Erlotinib in Patients With Neuroendocrine Tumors",
      "status": "TERMINATED",
      "last_update": "2020-09-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00873353",
      "title": "Trial to Evaluate the Efficacy and Safety of Tarceva and Capecitabine in Advanced Pancreatic Cancer Patients",
      "status": "COMPLETED",
      "last_update": "2010-08-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00878163",
      "title": "GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00885066",
      "title": "Gemcitabine, Capecitabine, and Erlotinib in Treating Patients With Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-04-23",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00922896",
      "title": "Trial of Erlotinib, Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2012-11-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00925769",
      "title": "ATX Study:A Study of Avastin (Bevacizumab), Tarceva (Erlotinib) and Xeloda (Capecitabine) in Patients With Locally Advanced and/or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-08-07",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00947167",
      "title": "A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors",
      "status": "TERMINATED",
      "last_update": "2017-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00954525",
      "title": "Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2025-05-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00987766",
      "title": "Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer",
      "status": "COMPLETED",
      "last_update": "2017-07-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01010945",
      "title": "Erlotinib, Gemcitabine and Nab-Paclitaxel in Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2024-11-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01013649",
      "title": "Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2026-02-23",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01108458",
      "title": "A Phase 2 Study of Pertuzumab and Erlotinib for Refractory Pancreatic Adenocarcinoma",
      "status": "TERMINATED",
      "last_update": "2017-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01181245",
      "title": "A Phase 1 Study of Safety and Bioactivity With FG-3019 in Combination With Gemcitabine and Erlotinib for Subjects With Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-08-06",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01210911",
      "title": "Metformin Combined With Chemotherapy for Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-04-21",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01214720",
      "title": "A Study of Avastin (Bevacizumab) Added to a Chemotherapeutic Regimen in Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-08-13",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01222689",
      "title": "Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2020-07-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01303029",
      "title": "Safety and Efficacy Study of Gemcitabine-erlotinib Versus Gemcitabine-erlotinib-capecitabine in Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-08-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01389440",
      "title": "Efficacy and Safety of a Neoadjuvant Treatment in Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2018-05-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01394120",
      "title": "Chemotherapy Selection Based on Therapeutic Targets for Advanced Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2012-03-27",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01454180",
      "title": "Study of Individualized Selection of Chemotherapy in Patients With Advanced Pancreatic Carcinoma According to Therapeutic Targets",
      "status": "COMPLETED",
      "last_update": "2015-10-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01505413",
      "title": "Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-04-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01505530",
      "title": "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2019-09-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01531712",
      "title": "Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable",
      "status": "TERMINATED",
      "last_update": "2017-08-29",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01555489",
      "title": "Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca",
      "status": "TERMINATED",
      "last_update": "2025-05-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01593995",
      "title": "EGF Ointment for Erlotinib Skin Lesion",
      "status": "COMPLETED",
      "last_update": "2014-11-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01600807",
      "title": "OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas",
      "status": "WITHDRAWN",
      "last_update": "2013-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01608841",
      "title": "The Role of EGFR Mutations in Pancreatic Cancer Patients Receiving Gemcitabine With or Without Erlotinib",
      "status": "UNKNOWN",
      "last_update": "2015-02-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01660971",
      "title": "Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-09-09",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01683422",
      "title": "Chemotherapy Plus Proton-chemotherapy for Locally Advanced Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2021-08-10",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01693419",
      "title": "S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-08-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01729481",
      "title": "Gemcitabine Plus Erlotinib in RASH-positive Patients With Metastatic Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2017-07-19",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02004262",
      "title": "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting",
      "status": "COMPLETED",
      "last_update": "2018-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02154737",
      "title": "Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-03-02",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02694536",
      "title": "A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-03-24",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02737228",
      "title": "Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2019-06-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03403049",
      "title": "Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2026-04-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05827614",
      "title": "Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications",
      "status": "TERMINATED",
      "last_update": "2026-08-19",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07802418",
      "title": "Molecularly Tailored Therapy in Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-09-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "GEFITINIB": {
    "n": 4,
    "n_observational": 1,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00075439",
      "title": "Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors",
      "status": "COMPLETED",
      "last_update": "2013-06-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00137761",
      "title": "Docetaxel in Combination With Iressa in Previously Treated Patients With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2009-11-02",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00177242",
      "title": "Study of Gefitinib and Docetaxel as Salvage Therapy in Advanced Pancreatic Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-01-18",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00234416",
      "title": "IRESSA Combined With Radiotherapy & Gemcitabine as First-Line Treatment in Locally Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2009-04-23",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "HUHMFG1": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02132403",
      "title": "(PM-01) IMPRIME PGG\u00ae With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2015-05-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ICOTINIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02024633",
      "title": "Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2015-07-15",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02278458",
      "title": "Combination of Icotinib and Gemcitabine as First-line Treatment in Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2015-05-22",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LABETUZUMAB": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00041639",
      "title": "Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2021-08-19",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00439179",
      "title": "A Trial of GW572016, Gemcitabine and Oxaliplatin for Metastatic Pancreaticobiliary Cancer Schema",
      "status": "COMPLETED",
      "last_update": "2020-02-17",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00447122",
      "title": "BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer",
      "status": "TERMINATED",
      "last_update": "2022-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00881621",
      "title": "Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00962312",
      "title": "Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LAPATINIB DITOSYLATE": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00447122",
      "title": "BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer",
      "status": "TERMINATED",
      "last_update": "2022-03-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00881621",
      "title": "Lapatinib and Capecitabine for Second Line Treatment of Pancreas Cancer",
      "status": "TERMINATED",
      "last_update": "2025-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00962312",
      "title": "Lapatinib Ditosylate and Capecitabine in Treating Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2014-12-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "LMB-100": {
    "n": 2,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02810418",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2022-03-15",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04034238",
      "title": "Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2023-08-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NERATINIB": {
    "n": 4,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT05372614",
      "title": "Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene",
      "status": "RECRUITING",
      "last_update": "2026-09-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06813079",
      "title": "Using Tumor Models to Determine Treatments",
      "status": "RECRUITING",
      "last_update": "2026-06-23",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03878524",
      "title": "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
      "status": "TERMINATED",
      "last_update": "2024-03-04",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03919292",
      "title": "Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca",
      "status": "SUSPENDED",
      "last_update": "2026-06-29",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "NIMOTUZUMAB": {
    "n": 20,
    "n_observational": 1,
    "n_active": 13,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT06389760",
      "title": "Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2024-10-31",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06722911",
      "title": "Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer",
      "status": "RECRUITING",
      "last_update": "2024-12-09",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06770452",
      "title": "HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients",
      "status": "RECRUITING",
      "last_update": "2026-06-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06840067",
      "title": "Clinical Study of Carbon Ion Radiotherapy for Pancreatic Cancer.",
      "status": "RECRUITING",
      "last_update": "2025-03-25",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07240766",
      "title": "HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation",
      "status": "RECRUITING",
      "last_update": "2026-02-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00561990",
      "title": "Nimotuzumab in Adults With Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2015-10-15",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02395016",
      "title": "A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2024-04-04",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT02945267",
      "title": "Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2016-10-26",
      "phase": "PHASE4",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05316480",
      "title": "Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2022-04-07",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06022276",
      "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors",
      "status": "UNKNOWN",
      "last_update": "2023-09-01",
      "phase": "NA",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06404840",
      "title": "Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study",
      "status": "UNKNOWN",
      "last_update": "2024-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06405685",
      "title": "Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis",
      "status": "UNKNOWN",
      "last_update": "2024-05-08",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06409429",
      "title": "Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2024-05-10",
      "phase": "PHASE2/PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06422156",
      "title": "SBRT Combined With Nimotuzumab and Mono-chemotherapy in Locally Advanced Pancreatic Cancer",
      "status": "UNKNOWN",
      "last_update": "2024-05-20",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06429904",
      "title": "Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-05-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06938503",
      "title": "AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-04-22",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07277452",
      "title": "Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2025-12-11",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07386704",
      "title": "Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer",
      "status": "ENROLLING_BY_INVITATION",
      "last_update": "2026-02-04",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07446270",
      "title": "Efficacy of Tunlametinib in Combination With Anti-EGFR Monoclonal Antibody in Patients With RAS-Mutated Advanced Gastrointestinal Malignancies",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-03-03",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07736612",
      "title": "A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer",
      "status": "NOT_YET_RECRUITING",
      "last_update": "2026-08-31",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "OSIMERTINIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT02465060",
      "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-08-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT03989115",
      "title": "Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC",
      "status": "COMPLETED",
      "last_update": "2023-06-26",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06630325",
      "title": "A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer",
      "status": "TERMINATED",
      "last_update": "2026-04-28",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "PANITUMUMAB": {
    "n": 15,
    "n_observational": 0,
    "n_active": 6,
    "n_withdrawn": 2,
    "trials": [
     {
      "nct": "NCT03384238",
      "title": "Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery",
      "status": "RECRUITING",
      "last_update": "2026-03-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06983743",
      "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-09-01",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06998940",
      "title": "Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations",
      "status": "RECRUITING",
      "last_update": "2026-05-22",
      "phase": "PHASE3",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094113",
      "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-07-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT07094204",
      "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors",
      "status": "RECRUITING",
      "last_update": "2026-05-18",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00004879",
      "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer",
      "status": "COMPLETED",
      "last_update": "2013-01-08",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00101907",
      "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer",
      "status": "TERMINATED",
      "last_update": "2014-03-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00550836",
      "title": "Erlotinib and Gemcitabine With or Without Panitumumab in Treating Patients With Metastatic Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00601627",
      "title": "Panitumumab, Chemotherapy, and External-Beam Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot be Removed by Surgery",
      "status": "COMPLETED",
      "last_update": "2017-04-05",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00613730",
      "title": "Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to Investigate Overall Survival as Primary Endpoint",
      "status": "TERMINATED",
      "last_update": "2014-01-06",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01130701",
      "title": "A Pilot Study to Evaluate the Efficacy and Safety of Neoadjuvant Chemoradiotherapy With Capecitabine, . . .",
      "status": "WITHDRAWN",
      "last_update": "2015-03-17",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01175733",
      "title": "Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer",
      "status": "COMPLETED",
      "last_update": "2017-03-20",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT04833959",
      "title": "Pilot Study of 89-Zr Panitumumab in Pancreas Cancer",
      "status": "WITHDRAWN",
      "last_update": "2024-06-21",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05121038",
      "title": "CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2024-12-17",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06194877",
      "title": "A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers",
      "status": "TERMINATED",
      "last_update": "2025-04-20",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SOTORASIB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 1,
    "n_withdrawn": 1,
    "trials": [
     {
      "nct": "NCT07563738",
      "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212",
      "status": "RECRUITING",
      "last_update": "2026-05-04",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT05251038",
      "title": "Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer",
      "status": "WITHDRAWN",
      "last_update": "2023-05-11",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "SS1(DSFV)-PE38": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00006981",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00066651",
      "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2015-04-30",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01362790",
      "title": "SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma",
      "status": "COMPLETED",
      "last_update": "2019-06-06",
      "phase": "PHASE1/PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "TUSAMITAMAB RAVTANSINE": {
    "n": 1,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT04659603",
      "title": "Tusamitamab Ravtansine Monotherapy and in Combination in Patients With CEACAM5-positive Advanced Solid Tumors",
      "status": "TERMINATED",
      "last_update": "2025-10-01",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "VANDETANIB": {
    "n": 3,
    "n_observational": 0,
    "n_active": 0,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT00551096",
      "title": "Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors",
      "status": "COMPLETED",
      "last_update": "2013-12-25",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT00681798",
      "title": "Dose Escalation Study With Zactima and Chemotherapy in Metastatic Pancreas Carcinoma",
      "status": "COMPLETED",
      "last_update": "2016-08-29",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT01601808",
      "title": "Clinical Trial Comparing Gemcitabine and Vandetanib Therapy With Gemcitabine Alone in Pancreatic Carcinoma",
      "status": "COMPLETED",
      "last_update": "2025-03-13",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     }
    ]
   },
   "ZOLBETUXIMAB": {
    "n": 2,
    "n_observational": 0,
    "n_active": 2,
    "n_withdrawn": 0,
    "trials": [
     {
      "nct": "NCT03816163",
      "title": "A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2026-07-14",
      "phase": "PHASE2",
      "study_type": "INTERVENTIONAL"
     },
     {
      "nct": "NCT06396091",
      "title": "A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer",
      "status": "ACTIVE_NOT_RECRUITING",
      "last_update": "2025-11-13",
      "phase": "PHASE1",
      "study_type": "INTERVENTIONAL"
     }
    ]
   }
  }
 }
}